Clinical trial · Interventional
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
Memory RT: Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
NCT07470606CI-TRIAL-00105524MemoryRTrecruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues. The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Memantine | Drug | — | UNRESOLVED |
| Raloxifene | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Group A: Standard of Care
- description
- Patients will start Memantine as SOC around the time of radiation. Memantine may be continued as SOC as prescribed by the treating physician after the 24 weeks.
- interventionNames
- Drug: Memantine
- type
- EXPERIMENTAL
- label
- Group B: Standard of Care plus raloxifene
- description
- Patients will start Memantine as SOC around the time of radiation. Memantine may be continued as SOC as prescribed by the treating physician after the 24 weeks. If randomized to group B patients will be recommended to start the assigned Raloxifene at least one week before their anticipated RT treatment start date.
- interventionNames
- Drug: Memantine
- Drug: Raloxifene
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years. 2. Ability to provide informed written consent in either English or Spanish. 3. All individuals of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an Intrauterine device (IUD)) with their partner from entry into the study through 24 weeks after the last dose of Raloxifene. 4. Patients undergoing radiation therapy to the brain as a part of solid tumor cancer therapy, using intensity modulated radiation therapy (IMRT) or whole brain radiation therapy (WBRT).Willingness to adhere to planned study drug regimen, including obtaining medication from an outside pharmacy via prescription. 5. Patients must have a creatinine clearance ≥ 50 mL/min (using Cockcroft-Gault Equation). 6. Patients must not have hepatic impairment greater than Child-Pugh Score "Class A". Exclusion Criteria: 1. History of prior radiotherapy to the brain. 2. Life expectancy of \< 6 months. 3. Radiation Therapy planned is ≤ 5 fractions (e.g.stereotactic radiosurgery (SRS)or Steriotactic radiotherapy (SRT), or 5-fraction whole brain). 4. Contraindications to taking memantine and/or raloxifene based on package inserts and the clinical judgement of the treating physician . 5. The subject is unable to undergo magnetic resonance imaging (MRI) scan (e.g., has an MRI incompatible pacemaker). 6. Conditions or situations which, in the opinion of the investigator, imply the patient will be unable or not suitable to complete trial requirements or at excessive risk from trial participation. 7. Known allergy to either of the medications (Memantine or Raloxifene) used in this study or their excipients. 8. Cognitive failure as assessed by Mini Mental State Exam (MMSE) score \<17
References
Publications (0)
Data not yet available
No reference posted for this study.